Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy.
Shami, P J
Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy. [electronic resource] - Leukemia Feb 2012 - 214-24 p. digital
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
1476-5551
10.1038/leu.2011.217 doi
Antineoplastic Agents--pharmacology
Fusion Proteins, bcr-abl--antagonists & inhibitors
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy
Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy. [electronic resource] - Leukemia Feb 2012 - 214-24 p. digital
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
1476-5551
10.1038/leu.2011.217 doi
Antineoplastic Agents--pharmacology
Fusion Proteins, bcr-abl--antagonists & inhibitors
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy